February 27, 2024
2 min watch
Save
VIDEO: Nab-paclitaxel shows promise for treatment of neuroendocrine tumors
In this video, Laleh Melstrom, MD, MS, discusses results from the NABNEC study, a randomized phase 2 study of nab-paclitaxel in combination with carboplatin as first-line treatment of gastrointestinal neuroendocrine carcinomas.
The experimental arm had higher response rates than the control arm, Melstrom, a surgical oncologist at City of Hope, said of the study presented at ASCO Gastrointestinal Cancers Symposium.
Melstrom also noted a 24-month overall survival of 25% in the experimental group compared with 17% in the control.
"There is a signal with nab-paclitaxel — this may be an option for patients that may not be candidates for etoposide," said Melstrom.
Reference:
- Chantrill L, et al. Abstract 589. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Melstrom reports no relevant financial disclosures.